Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Genetics

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 23 articles:
HTML format



Single Articles


    August 2019
  1. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    PubMed     Abstract available


    July 2019
  2. BRAR G, Blais EM, Joseph Bender R, Brody JR, et al
    Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
    Br J Cancer. 2019;121:264-270.
    PubMed     Abstract available


  3. WILLEMSEN AECAB, Krausz S, Ligtenberg MJL, Grunberg K, et al
    Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
    Br J Cancer. 2019;121:34-36.
    PubMed     Abstract available


    April 2019
  4. IACHETTA F, Bonelli C, Romagnani A, Zamponi R, et al
    The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study.
    Br J Cancer. 2019;120:834-839.
    PubMed     Abstract available


    March 2019
  5. GIOVANNINI C, Salzano AM, Baglioni M, Vitale M, et al
    Brivanib in combination with Notch3 silencing shows potent activity in tumour models.
    Br J Cancer. 2019;120:601-611.
    PubMed     Abstract available


    October 2018
  6. WILLIAMS LA, Mills L, Hooten AJ, Langer E, et al
    Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0277.
    PubMed     Abstract available


  7. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Abstract available


    August 2018
  8. KRISP C, Parker R, Pascovici D, Hayward NK, et al
    Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
    Br J Cancer. 2018 Aug 17. pii: 10.1038/s41416-018-0227.
    PubMed     Abstract available


    July 2018
  9. SAHA A, Harowicz MR, Grimm LJ, Kim CE, et al
    A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0185.
    PubMed     Abstract available


    March 2018
  10. SHINOZAKI E, Yoshino T, Tsuchihara K
    Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Ant
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0040.
    PubMed    


  11. DANKNER M, Rose AAN
    Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0012.
    PubMed    


  12. EL ANSARI R, Craze ML, Diez-Rodriguez M, Nolan CC, et al
    The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    Br J Cancer. 2018 Mar 16. pii: 10.1038/s41416-018-0038.
    PubMed     Abstract available


    November 2017
  13. ZHANG J, Hao N, Liu W, Lu M, et al
    In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
    Br J Cancer. 2017;117:1676-1684.
    PubMed     Abstract available


    October 2017
  14. RUZZO A, Graziano F, Galli F, Galli F, et al
    Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Br J Cancer. 2017;117:1269-1277.
    PubMed     Abstract available


  15. SHINOZAKI E, Yoshino T, Yamazaki K, Muro K, et al
    Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensi
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    August 2017
  16. LEVI F, Karaboue A, Saffroy R, Desterke C, et al
    Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  17. SARASWAT M, Makitie A, Agarwal R, Joenvaara S, et al
    Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics.
    Br J Cancer. 2017;117:376-384.
    PubMed     Abstract available


    June 2017
  18. ALVI MA, Loughrey MB, Dunne P, McQuaid S, et al
    Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
    Br J Cancer. 2017 Jun 8. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    April 2017
  19. HEQUET D, Huchon C, Baffert S, Alran S, et al
    Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.
    Br J Cancer. 2017 Apr 25. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2017
  20. HU H, Shu M, He L, Yu X, et al
    Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer.
    Br J Cancer. 2017 Jan 31. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    November 2016
  21. GROSSI F, Rijavec E, Genova C, Barletta G, et al
    Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    September 2016
  22. LARKIN SE, Johnston HE, Jackson TR, Jamieson DG, et al
    Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    May 2016
  23. MESEURE D, Vacher S, Lallemand F, Alsibai KD, et al
    Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
    Br J Cancer. 2016 May 12. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Genetics is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: